Wuhan Xirui Pharmaceutical Technology Co., Ltd.

The pharmacokinetic parameters were used as the primary endpoints to compare the pharmacokinetic behaviors of the test preparation Edoxaban Tosylate Tablets (Specification: 60 mg, licensee: Wuhan Xirui Pharmaceutical Technology Co., Ltd.) and the reference preparation Edoxaban Tosylate Tablets (Specification: 60 mg, licensee: Daiichi Sankyo Europe GmbH, trade name: Lixiana®) in healthy subjects after oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations. The safety of the test preparation Edoxaban Tosylate Tablets and the reference preparation Edoxaban Tosylate Tablets in healthy subjects was observed.

The pharmacokinetic parameters were used as the primary endpoints to compare the pharmacokinetic behaviors of the test preparation Perindopril Amlodipine Tablets (III) (licensed by Wuhan Xirui Pharmaceutical Technology Co., Ltd.) and the reference preparation Perindopril Amlodipine Tablets (III) (licensed by Les Laboratoires Servier, trade name: Kaisuda®) in healthy subjects after oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations. The safety of the test preparation Perindopril Amlodipine Tablets (III) and the reference preparation Perindopril Amlodipine Tablets (III) in healthy subjects was observed.